29 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Tuning the Reactivity of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Optimal 
Rigel Pharmaceuticals
Optimization of Pharmacokinetic and In Vitro Safety Profile of a Series of Pyridine Diamide Indirect AMPK Activators.
Rigel Pharmaceuticals
Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate.
Rigel Pharmaceuticals
Structure activity relationships leading to the identification of the indirect activator of AMPK, R419.
Rigel Pharmaceuticals
Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors.
Rigel Pharmaceuticals
Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy.
Rigel Pharmaceuticals
Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus.
Rigel Pharmaceuticals
GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF
Deciphera Pharmaceuticals
Phosphonate linkers and their use to facilitate cellular retention of compounds
Merck Sharp & Dohme
Small molecule activators of Parkin enzyme function
Mayo Foundation For Medical Education and Research
Alpha-truxillic acid derivatives and pharmaceutical compositions thereof
The State University of New York
HDAC inhibitor compounds and methods of treatment
University of Florida Research Foundation
Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof
Jiangsu Hengrui Medicine
Synthesis, Biological Evaluation, and Docking of Dihydropyrazole Sulfonamide Containing 2-hydroxyphenyl Moiety: A Series of Novel MMP-2 Inhibitors.
Nanjing University